Clinical Study | Office of Clinical Research

A Phase III Trial Of 6 Versus 12 Treatments Of Adjuvant Folfox Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer.

Posted Date: May 15, 2019

Investigator: Olugbenga Olowokure
Type of Study: Drug

This study will evaluate the good and bad effects of an oral drug called celecoxib when given in combination with FOLFOX chemotherapy. Celecoxib is approved by the FDA to treat arthritis and to prevent colon polyps in families with a genetic risk for colon cancer. The addition of celecoxib to FOLF

Criteria:

Eligible Patients Must Have Cancer Of The Colon, Which Has Been Surgically Removed, But Has Spread T

Keywords:

Calgb 80702, Colon Cancer, Gastroinestinal Canc, Gi Cancer, Resected

For More Information:

Uc Cancer Center
513-584-7698
kastla@ucmail.uc.edu

Name*
First Last
Gender*
- Male
- Female
Age*
Phone*
Email*
How did you hear about us?*
Future Communication*
- By submitting this form, I am agreeing to receive future communication about participating in an upcoming research study.
CAPTCHA
This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.
List